| A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis A Vecchione, B Belletti, F Lovat, S Volinia, G Chiappetta, S Giglio, ... Proceedings of the National Academy of Sciences 110 (24), 9845-9850, 2013 | 208 | 2013 |
| The use of bevacizumab in non-small cell lung cancer: an update S Lauro, CE Onesti, R Righini, P Marchetti Anticancer research 34 (4), 1537-1545, 2014 | 114 | 2014 |
| The sexist behaviour of immune checkpoint inhibitors in cancer therapy? A Botticelli, CE Onesti, I Zizzari, B Cerbelli, P Sciattella, M Occhipinti, ... Oncotarget 8 (59), 99336, 2017 | 92 | 2017 |
| Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines F Mazzuca, CE Onesti, M Roberto, M Di Girolamo, A Botticelli, P Begini, ... Oncotarget 9 (39), 25714, 2018 | 58 | 2018 |
| CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis CE Onesti, G Jerusalem Expert review of anticancer therapy 21 (3), 283-298, 2021 | 52 | 2021 |
| High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art R Falcone, M Roberto, C D’Antonio, A Romiti, A Milano, CE Onesti, ... Digestive and Liver Disease 48 (12), 1503-1505, 2016 | 45 | 2016 |
| Expected medium-and long-term impact of the COVID-19 outbreak in oncology CE Onesti, M Tagliamento, G Curigliano, N Harbeck, R Bartsch, ... JCO global oncology 5 (1), 162-172, 2021 | 43 | 2021 |
| Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy CE Onesti, F Boemer, C Josse, S Leduc, V Bours, G Jerusalem Journal of translational medicine 17, 1-11, 2019 | 41 | 2019 |
| Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment CE Onesti, P Frères, G Jerusalem Journal of Thoracic Disease 11 (1), 35, 2019 | 41 | 2019 |
| Oncological care organisation during COVID-19 outbreak CE Onesti, HS Rugo, D Generali, M Peeters, K Zaman, H Wildiers, ... ESMO open 5 (4), e000853, 2020 | 36 | 2020 |
| Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival M Roberto, A Botticelli, L Strigari, M Ghidini, CE Onesti, M Ratti, I Benzoni, ... Medical oncology 35, 1-9, 2018 | 34 | 2018 |
| Changes of microbiome profile during nivolumab treatment in NSCLC patients. A Botticelli, L Putignani, I Zizzari, F Del Chierico, S Reddel, F Di Pietro, ... Journal of Clinical Oncology 36 (15_suppl), e15020-e15020, 2018 | 32 | 2018 |
| Molecular detection of EMT markers in circulating tumor cells from metastatic non-small cell lung cancer patients: potential role in clinical practice A Milano, F Mazzetta, S Valente, D Ranieri, L Leone, A Botticelli, ... Analytical Cellular Pathology 2018, 2018 | 28 | 2018 |
| Continuous, low-dose capecitabine for patients with recurrent colorectal cancer A Romiti, CE Onesti, M Roberto, V Barucca, S Tomao, C D’Antonio, ... Medical Oncology 32, 1-5, 2015 | 27 | 2015 |
| Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know C D'ANTONIO, A Milano, R Righini, CE Onesti, M Bassanelli, R Falcone, ... Anticancer research 34 (10), 5241-5250, 2014 | 27 | 2014 |
| Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse CE Onesti, C Josse, D Boulet, J Thiry, B Beaumecker, V Bours, ... Oncoimmunology 9 (1), 1761176, 2020 | 26 | 2020 |
| Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant … CE Onesti, C Josse, A Poncin, P Frères, C Poulet, V Bours, G Jerusalem Oncotarget 9 (72), 33719, 2018 | 26 | 2018 |
| Immunity and breast cancer: focus on eosinophils A Poncin, CE Onesti, C Josse, D Boulet, J Thiry, V Bours, G Jerusalem Biomedicines 9 (9), 1087, 2021 | 22 | 2021 |
| Precision medicine for metastatic breast cancer. AF Deluche E, Onesti E Am Soc Clin Oncol Educ Book 35, e2-e7, 2015 | 22 | 2015 |
| Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine M Roberto, A Romiti, A Botticelli, F Mazzuca, L Lionetto, G Gentile, I Paris, ... European journal of clinical pharmacology 73, 157-164, 2017 | 20 | 2017 |
Maurizio SimmacoUniversità La Sapienza - Azienda Ospedaliera Sant'Andrea - RomaVerified email at uniroma1.it
